During the past decade, Sapporo-Kosei General Hospital conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 16 clinical trials were completed, i.e. on average, 61.5% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 12 clinical trials were completed. i.e. 120% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sapporo-Kosei General Hospital" #1 sponsor was "Pfizer" with 7 trials, followed by "Eli Lilly and Company" with 4 trials sponsored, "Gilead Sciences" with 4 trials sponsored, "Takeda" with 4 trials sponsored and "Galapagos NV" with 4 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sapporo-Kosei General Hospital" #1 collaborator was "Gilead Sciences" with 3 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator, "Galapagos NV" with 1 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator and "Novo Nordisk A/S" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Sapporo-Kosei General Hospital" are "Ulcerative Colitis" (13 trials), "Crohn's Disease" (10 trials), "Carcinoma, Hepatocellular" (4 trials), "Nonalcoholic Steatohepatitis" (3 trials) and "Advanced Hepatocellular Carcinoma" (2 trials). Many other conditions were trialed in "Sapporo-Kosei General Hospital" in a lesser frequency.

Most popular intervention types in "Sapporo-Kosei General Hospital" are "Drug" (33 trials), "Biological" (2 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "CP-690,550" (4 trials), "Filgotinib" (4 trials), "Guselkumab" (3 trials) and "Mirikizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Sapporo-Kosei General Hospital" are 33 trials for "All" genders.

Currently, there are NaN active trials in "Sapporo-Kosei General Hospital". undefined are not yet recruiting, 8 are recruiting, 7 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 13 completed trials in Sapporo-Kosei General Hospital, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Sapporo-Kosei General Hospital, 1 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 22 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".